Key Highlights
- Phil Tennant appointed as Chief Commercial Officer at Precigen.
- Focus on commercial readiness for PRGN-2012 gene therapy.
- Tennant’s extensive experience in biotech and pharmaceutical industries.
- Significant expertise in oncology and rare diseases.
- Reports to Helen Sabzevari, President and CEO of Precigen.
Source: PR Newswire
Notable Quotes
- “Phil is a recognized global commercial leader with an impressive 30-plus year track record building commercial organizations and scaling commercial operations to drive revenue growth for both niche and blockbuster therapeutics.” — Helen Sabzevari, PhD, President and CEO at Precigen
- “This is a tremendously exciting time to join Precigen. I am thrilled to be able to collaborate with the team to further commercial readiness work already underway and build out Precigen’s commercial strategy and operations to support the first potential commercial launch for the company’s lead asset, PRGN-2012.” — Phil Tennant, Chief Commercial Officer at Precigen
SoHC's Take
The appointment of Phil Tennant as Chief Commercial Officer marks a pivotal moment for Precigen as it transitions towards becoming a commercial-stage company. Tennant’s extensive background in leading successful product launches and driving significant growth in global markets positions Precigen well for the impending launch of its PRGN-2012 gene therapy for recurrent respiratory papillomatosis. His proven track record in oncology and rare diseases will be invaluable as the company aims to provide innovative, life-changing therapies to patients with unmet medical needs.
